The global scientific community's attention has turned to COVID-19, a pandemic that has swept across the world since emerging in China in late December 2019. The future is now.

The causative agent of COVID-19, the coronavirus SARS-CoV-2, has no vaccine, and no biologics or small molecules have yet been approved to treat it. There is a big opportunity for protein engineering to make an impact on this disease without a cure.

This whitepaper examines the current challenges and opportunities in developing protein therapeutics to treat COVID-19, looking at existing case studies across preclinical development, targeting and regulatory approval.

To read the whitepaper, just click on the image below.

Have any questions about the report or interested in sponsoring a future whitepaper? Email andrew.burrows@informa.com.